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To the Editor,
A 19-year-old male presented in 1999 with anemia, increased
inflammatory parameters and knee complaints, based on dif-
fuse-type giant cell tumor (DGCT). In 2010, a low femoral
amputation was performed after several functional joint spar-
ing surgeries and a short unsuccessful period of imatinib
400mg once daily (OD) therapy [1]. Histopathology showed
destructive DGCT with secondary changes due to imatinib
treatment, but no signs of malignancy.
Four years later, he presented with fever, sweating, ano-
rexia, weight loss, palpitations and anemia. FDG-positron
emission tomography (PET)-computed tomography (CT) scan
showed new pulmonary lesions and mediastinal lymphaden-
opathy. A cytological lymph node biopsy proved metastastic
DGCT. Imatinib 400mg OD and predisolone 30mg OD were
started. No other immune-modulating therapy has been
administered. Two months after start of imatinib and prednis-
olone, his clinical condition deteriorated with weight loss,
fever and inflammation (Table 1). FDG-uptake showed
increased metabolic activity of metastases. To prevent atelec-
tasis, the highly metabolically active right hilar metastasis was
irradiated (30Gy in 10 fractions; Figure 1(a)). During radiother-
apy, his condition rapidly deteriorated with high fevers, pro-
found anemia, hypoalbumenia, decreased
sodium, hyperglycemia and pulmonary infection (Table 1).
Unexpectedly, within two weeks after completing radiotherapy,
he clinically improved and his inflammatory laboratory values
decreased (Table 1). FDG-PET-CT showed response of the
right irradiated hilar lesion, volumetric and metabolic
response of left-sided non-irradiated pulmonary metastases
and an increase of uptake in one mediastinal lymph node
(Figure 1(b) and (c)). This phenomenon is called abscopal
effect. It persisted for six months, after which he progressed
and died from disease three months later.
Discussion
The abscopal effect induced by radiotherapy is rare and is
mostly reported in tumor types considered immunogenic such
CONTACT Winette T. A. van der Graaf winette.vandergraaf@icr.ac.uk Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The
Netherlands; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK
 2016 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1510 LETTERS TO THE EDITOR
as melanoma, but has to our knowledge never been
described in mesenchymal malignancies [2]. The immune sys-
tem has been proposed as the key component of this absco-
pal effect [3]. Local radiotherapy induces cell death and
release of immunogenic factors, leading to host immune
responses. Damage-associated molecular patterns trigger den-
dritic cells, resulting in improved antigen presentation to T
cells [2,4]. Pharmacological modification of the abscopal effect
has been suggested for immune checkpoint inhibitors and
granulocyte-macrophage colony-stimulating factor [4–7].
Here we report a patient with malignant DGCT with
marked inflammatory symptoms and laboratory parameters,
who demonstrated a systemic benefit from local radiotherapy
by an abscopal effect. Tenosynovial giant cell tumors are rare
mesenchymal lesions that arise from the synovial lining of
articular spaces, bursal sacs, and tendon sheaths. The diffuse-
type is an aggressive multifocal proliferation of synovial-like
mononuclear cells with inflammatory infiltrates. Metastases of
DGCT are extremely rare. The current treatment strategies
have recently been reviewed [8]. The inflammatory nature
and the observed abscopal effect plea for considering immu-
notherapeutic approaches in this disease.
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Table 1. Laboratory results.
Parameter (normal range)
Before start of
radiotherapy
Day 5 of radiotherapy
(10 3 Gy)
Last day of
radiotherapy
3 weeks after completing
radiotherapy
Hemoglobulin (8.4–10.8mmol/l) 5.1 5.1a 5.8 6.7
Leukocytes (4.0–11.0 109/l) 17.4 15.1 13.2 16.8
Platelets (150–400 109/l) 811 609 567 445
Neutrophils (2–7.5 109/l) 12.7 12.4 11.4
Lymphocytes (1–3.5 109/l) 2.4 0.6 0.5
Monocytes (0.3–1.0 109/l) 2.3 2.0 1.3
Sodium (135–145mmol/l) 134 129 127 135
Albumin (35–50 g/l) 13 10 10 17
CRP (<10mg/ml) 200 225 82
aErythrocyte transfusion was administered after this measurement. CRP: C-reactive protein.
Figure 1. Computed tomography (CT) (left column), FDG-positron emission tomography (PET) (middle column) and combined FDG-PET-CT (right column) before the
start (pre) and after completion (post) of radiotherapy. (a) showing high uptake of FDG in the right hilar diffuse-type giant cell tumor metastasis before the start of
radiotherapy and impressive decrease in FDG-uptake, corresponding with metabolic response 3 weeks after completion of radiotherapy. Abscopal effect in the left pul-
monary metastases (b) and mediastinal lymphadenopathy (c), showing a volume response on CT and metabolic response on FDG-PET-CT in the pulmonary lesions as
well as increased uptake in a mediastinal lymph node on FDG-PET-CT, in keeping with an immunological reaction.
ACTA ONCOLOGICA 1511
tenosynovial giant cell tumor/pigmented villonodular synovitis.
Cancer 2012;118:1649–55.
2. Reynders K, Illidge T, Siva S, et al. The abscopal effect of local
radiotherapy: using immunotherapy to make a rare event clinically
relevant. Cancer Treat Rev 2015;41:503–10.
3. Formenti SC, Demaria S. Systemic effects of local radiotherapy.
Lancet Oncol 2009;10:718–26.
4. Levy A, Chargari C, Marabelle A, et al. Can immunostimulatory
agents enhance the abscopal effect of radiotherapy? Eur J Cancer
2016;62:36–45.
5. Grimaldi AM, Simeone E, Giannarelli D, et al. Abscopal effects of
radiotherapy on advanced melanoma patients who progressed
after ipilimumab immunotherapy. Oncoimmunology 2014;3:e28780.
6. Chandra RA, Wilhite TJ, Balboni TA, et al. A systematic evaluation
of abscopal responses following radiotherapy in patients with
metastatic melanoma treated with ipilimumab. Oncoimmunology
2015;4:e1046028.
7. Golden EB, Chhabra A, Chachoua A, et al. Local radiotherapy and
granulocyte-macrophage colony-stimulating factor to generate
abscopal responses in patients with metastatic solid tumors:
a proof-of-principle trial. Lancet Oncol 2015;16:795–803.
8. Staals EL, Ferrari S, Donati DM, et al. Diffuse-type tenosynovial giant
cell tumour: Current treatment concepts and future perspectives.
Eur J Cancer 2016;63:34–40.
LETTER TO THE EDITOR
The relative biological effectiveness of carbon ion irradiations of the rat spinal
cord increases linearly with LET up to 99 keV/lm
Maria Saagera,b,c, Christin Glowaa,b,c, Peter Peschkec,d, Stephan Bronsc,e, Rebecca Gr€unf, Michael Scholzf,
Peter E. Hubera,c,d, J€urgen Debusa,c and Christian P. Kargerb,c
aDepartment of Radiation Oncology, University Hospital of Heidelberg, Heidelberg, Germany; bDepartment of Medical Physics in Radiation
Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; cNational Center for Radiation Research in Oncology (NCRO),
Heidelberg Institute for Radiation Oncology (HIRO), Heidelberg, Germany; dClinical Cooperation Unit Molecular Radiooncology, German Cancer
Research Center (DKFZ), Heidelberg, Germany; eHeidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany; fDepartment of Biophysics,
Helmholtz Center for Heavy Ion Research (GSI), Darmstadt, Germany
ARTICLE HISTORY Received 16 August 2016; revised 11 October 2016; accepted 15 October 2016
To the Editor,
Based on preliminary work at the Lawrence Berkley
Laboratory [1], carbon ion beams developed to a mature
technology in radiotherapy, which has now been applied suc-
cessfully in patients for two decades [2–4]. As in proton radio-
therapy, the depth-dose profile (Bragg peak) of carbon ions
allows for highly conformal irradiations of the tumor.
However, the rise of the relative biological effectiveness (RBE)
with penetration depth towards the distal end of a spread-
out Bragg peak (SOBP) is much more pronounced for carbon
ions than for protons [5]. Quantitatively, the RBE is given by
the ratio of a photon and an isoeffective carbon ion dose at a
defined endpoint. However, the RBE is a complex quantity
depending on particle type, linear energy transfer (LET), dose,
and also on biological properties of the irradiated tissue. To
consider the increased effectiveness of carbon ions, the RBE
is calculated by bio-mathematical models. In Europe, clinical
treatment planning is done using the local effect model
(LEM), which is presently available in two versions (LEM I [6]
and IV [7]). Although LEM I has been used for all patients so
far, LEM IV was extended by including information on the
spatial DNA double stand break density. It is, however, an
open question, which version is more accurate.
To validate the LEM in vivo, the RBE for radiation-induced
myelopathy in the rat spinal cord has been determined in
several studies [8–11] and comparisons with LEM predictions
were made. In these studies RBEs were calculated for the tol-
erance doses at 50% complication probability (TD50) deter-
mined from dose-response experiments. Although initial
studies [8,9] demonstrated a strong dose-dependence of the
RBE, the LET-dependence was not investigated in detail.
This was the starting point of a second series of experi-
ments, where the rat spinal cord was irradiated with single and
split doses at six different positions of a 6 cm SOBP covering a
LET range from 16 to 99 keV/lm [10,11]. These data showed a
linear increase of RBE with LET, where the slope of the curve
increased with decreasing fractional dose [11]. For the single
fraction experiment at 99 keV/lm, however, an inconsistently
low RBE combined with a shallow dose-response curve was
found. As this was only observed in the single but not in the
split dose experiments, we repeated the 99 keV/lm single dose
experiment and report here on the results.
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